Cytokinetic effects of Wee1 disruption in pancreatic cancer

References

• Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006; 21(1):3-9; PMID:16314342; http://dx.doi.org/10.1093/mutage/gei063
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang X, Teng L, Legerski RJ. DNA damage checkpoint recovery and cancer development. Exp Cell Res 2015; 334(2):350-8; PMID:25842165; http://dx.doi.org/10.1016/j.yexcr.2015.03.011
   PubMed Web of Science ®Google Scholar
• Kousholt AN, Menzel T, Sorensen CS. Pathways for genome integrity in G2 phase of the cell cycle. Biomolecules 2012; 2(4):579-607; PMID:24970150; http://dx.doi.org/10.3390/biom2040579
   PubMedGoogle Scholar
• Medema RH, Macurek L. Checkpoint control and cancer. Oncogene 2012; 31(21):2601-13; PMID:21963855; http://dx.doi.org/10.1038/onc.2011.451
   PubMed Web of Science ®Google Scholar
• Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011; 10(13):2121-8; PMID:21610326; http://dx.doi.org/10.4161/cc.10.13.16398
   PubMed Web of Science ®Google Scholar
• Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013; 12(19):3159-64; PMID:24013427; http://dx.doi.org/10.4161/cc.26062
   PubMed Web of Science ®Google Scholar
• Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9(7):514-22; PMID:20107315; http://dx.doi.org/10.4161/cbt.9.7.11115
   PubMed Web of Science ®Google Scholar
• Kaistha BP, Honstein T, Muller V, Bielak S, Sauer M, Kreider R, Fassan M, Scarpa A, Schmees C, Volkmer H, et al. Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells. Br J Cancer 2014; 111(9):1780-7; PMID:25137017; http://dx.doi.org/10.1038/bjc.2014.460
   PubMed Web of Science ®Google Scholar
• Slee RB, Grimes BR, Bansal R, Gore J, Blackburn C, Brown L, Gasaway R, Jeong J, Victorino J, March KL, et al. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Mol Cancer Ther 2014; 13(2):307-15; PMID:24282275; http://dx.doi.org/10.1158/1535-7163.MCT-13-0324
   PubMed Web of Science ®Google Scholar
• Vriend LE, De Witt Hamer PC, Van Noorden CJ, Wurdinger T. WEE1 inhibition and genomic instability in cancer. Biochim Biophys Acta 2013; 1836(2):227-35; PMID:23727417
   PubMed Web of Science ®Google Scholar
• Ferrell JE, Jr. Feedback regulation of opposing enzymes generates robust, all-or-none bistable responses. Curr Biol 2008; 18(6):R244-R245; PMID:18364225; http://dx.doi.org/10.1016/j.cub.2008.02.035
   PubMed Web of Science ®Google Scholar
• Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011; 17(17):5638-48; PMID:21799033; http://dx.doi.org/10.1158/1078-0432.CCR-11-0650
   PubMed Web of Science ®Google Scholar
• Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, Collins J, Chen AP, Doroshow JH, Kummar S. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol 2015; 33(30):3409-15; PMID:25964244
   PubMed Web of Science ®Google Scholar
• Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, et al. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther 2015; 14(2):608-19; PMID:25504633; http://dx.doi.org/10.1158/1535-7163.MCT-14-0735-T
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, De OE, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17(9):2799-806; PMID:21389100; http://dx.doi.org/10.1158/1078-0432.CCR-10-2580
   PubMed Web of Science ®Google Scholar
• Beck H, Nahse-Kumpf V, Larsen MS, O'Hanlon KA, Patzke S, Holmberg C, Mejlvang J, Groth A, Nielsen O, Syljuåsen RG, et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 2012; 32(20):4226-36; PMID:22907750; http://dx.doi.org/10.1128/MCB.00412-12
   PubMed Web of Science ®Google Scholar
• Sorensen CS, Syljuasen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res 2012; 40(2):477-86; PMID:21937510; http://dx.doi.org/10.1093/nar/gkr697
   PubMed Web of Science ®Google Scholar
• Beck H, Nahse V, Larsen MS, Groth P, Clancy T, Lees M, Jørgensen M, Helleday T, Syljuåsen RG, Sørensen CS. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol 2010; 188(5):629-38; PMID:20194642; http://dx.doi.org/10.1083/jcb.200905059
   PubMed Web of Science ®Google Scholar
• Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012; 2(6):524-39; PMID:22628408; http://dx.doi.org/10.1158/2159-8290.CD-11-0320
   PubMed Web of Science ®Google Scholar
• Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther 2013; 12(8):1442-52; PMID:23699655; http://dx.doi.org/10.1158/1535-7163.MCT-13-0025
   PubMed Web of Science ®Google Scholar
• Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8(11):2992-3000; PMID:19887545; http://dx.doi.org/10.1158/1535-7163.MCT-09-0463
   PubMed Web of Science ®Google Scholar
• Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther 2013; 12(12):2675-84; PMID:24121103; http://dx.doi.org/10.1158/1535-7163.MCT-13-0424
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov 2014; 4(3):280-91; PMID:24550033; http://dx.doi.org/10.1158/2159-8290.CD-13-0337
   PubMed Web of Science ®Google Scholar
• Sarcar B, Kahali S, Prabhu AH, Shumway SD, Xu Y, Demuth T, Chinnaiyan P. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 2011; 10(12):2405-14; PMID:21992793; http://dx.doi.org/10.1158/1535-7163.MCT-11-0469
   PubMed Web of Science ®Google Scholar
• Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res 2014; 20(19):5085-96; PMID:25117293; http://dx.doi.org/10.1158/1078-0432.CCR-14-1038
   PubMed Web of Science ®Google Scholar
• Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, et al. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer 2015; 113(3):425-32; PMID:26180923; http://dx.doi.org/10.1038/bjc.2015.220
   PubMed Web of Science ®Google Scholar
• Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK, et al. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann Surg Oncol 2015; 22(7):2352-8; PMID:25564157; http://dx.doi.org/10.1245/s10434-014-4274-5
   PubMed Web of Science ®Google Scholar
• Jacobberger JW, Sramkoski RM, Stefan T. Multiparameter cell cycle analysis. Methods Mol Biol 2011; 699:229-49; PMID:21116986; http://dx.doi.org/10.1007/978-1-61737-950-5_11
   PubMedGoogle Scholar
• Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH, Sayad A, Mero P, Lawo S, et al. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol Syst Biol 2013; 9:696; PMID:24104479; http://dx.doi.org/10.1038/msb.2013.54
   PubMed Web of Science ®Google Scholar
• Kreutz B, Hajicek N, Yau DM, Nakamura S, Kozasa T. Distinct regions of Galpha13 participate in its regulatory interactions with RGS homology domain-containing RhoGEFs. Cell Signal 2007; 19(8):1681-9; PMID:17449226; http://dx.doi.org/10.1016/j.cellsig.2007.03.004
   PubMed Web of Science ®Google Scholar
• Gardner JA, Ha JH, Jayaraman M, Dhanasekaran DN. The gep proto-oncogene Galpha13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells. Pancreas 2013; 42(5):819-28; PMID:23508014; http://dx.doi.org/10.1097/MPA.0b013e318279c577
   PubMed Web of Science ®Google Scholar
• Chen Z, Guo L, Hadas J, Gutowski S, Sprang SR, Sternweis PC. Activation of p115-RhoGEF requires direct association of Galpha13 and the Dbl homology domain. J Biol Chem 2012; 287(30):25490-500; PMID:22661716; http://dx.doi.org/10.1074/jbc.M111.333716
   PubMed Web of Science ®Google Scholar
• Chang Q, Jurisica I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically-grown primary xenografts of human pancreatic cancer. Cancer Res 2011; 71(8):3110-20; PMID: 21343390
   PubMed Web of Science ®Google Scholar
• Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002; 1(10):777-83; PMID:12492110
   PubMed Web of Science ®Google Scholar
• De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Wurdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 2011; 17(13):4200-7; PMID:21562035; http://dx.doi.org/10.1158/1078-0432.CCR-10-2537
   PubMed Web of Science ®Google Scholar
• Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003; 9(4):493-501; PMID:12649500; http://dx.doi.org/10.1261/rna.2192803
   PubMed Web of Science ®Google Scholar
• Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72(11):8463-71; PMID:9765382
   PubMed Web of Science ®Google Scholar
• Allalunis-Turner MJ, Siemann DW. Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes. Br J Cancer 1986; 54(4):615-22; PMID:3535863; http://dx.doi.org/10.1038/bjc.1986.217
   PubMed Web of Science ®Google Scholar
• Blakely K, Ketela T, Moffat J. Pooled lentiviral shRNA screening for functional genomics in mammalian cells. Methods Mol Biol 2011; 781:161-82; PMID:21877282; http://dx.doi.org/10.1007/978-1-61779-276-2_9
   PubMedGoogle Scholar